(Q51550717)

6 April 2018

title

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. (English)

1 reference

6 April 2018

0 references

0 references

1 reference

1 reference

Patel J

1

1 reference

6 April 2018

Anderson RJ

series ordinal

2

1 reference

6 April 2018

Rappaport EB

series ordinal

3

1 reference

6 April 2018

publication date

1 May 1999

1 reference

6 April 2018

Diabetes, Obesity and Metabolism

published in

1 reference

6 April 2018

volume

1

1 reference

6 April 2018

issue

3

1 reference

6 April 2018

page(s)

165-172

1 reference

6 April 2018

Pathogenesis of NIDDM. A balanced overview

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

End-stage renal disease attributable to diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

[[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

The peroxisome proliferator-activated receptors: ligands and activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.1999.00020.X

10.1046/J.1463-1326.1999.00020.X

21 January 2018

Identifiers

DOI

1 reference

6 April 2018

1 reference

6 April 2018